Ojemda is indicated as monotherapy for the treatment of patients 6 months of age and older with paediatric low-grade glioma (LGG) harbouring a BRAF fusion or rearrangement, or BRAF V600 mutation, who have progressed after one or more prior systemic therapies (for biomarkers-based patient selection, see section 4.2)
The same active substances on other registers, the same brand first.
The national registers that list this EU medicine.
Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.
The official texts, at the regulator.
Compiled by Prognia from the public register below; the register’s text is the official one.
Source: European Medicines Agency, EPAR list (imported 10 June 2026).
Licence: EMA content, reuse with acknowledgement · Added 10 Jun 2026
Report an error or request removalCorrections from the holder or the register are welcome.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
